ERBB2 and cancer: Favorable clinical outcome was also noted when trastuzumab combined with Paclitaxel was administered after doxorubicin and cyclophosphamide to patients enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 and the North Central Cancer Treatment Group (NCCTG) N9831 trials with surgically removed HER2-positive breast cancers [101].